Article: Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEffects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study
AuthorsLam, DCL1
Lam, B1
Wong, MKY1
Lu, C1
Au, WY1
Tse, EWC1
Leung, AYH1
Kwong, YL1
Liang, RHS1
Lam, WK1
Ip, MSM1
Lie, AKW1
KeywordsAzithromycin
Bronchiolitis obliterans syndrome (BOS)
Hematopoietic SCT (HSCT)
Issue Date2011
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
CitationBone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556 [How to Cite?]
DOI: http://dx.doi.org/10.1038/bmt.2011.1
AbstractBronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. © 2011 Macmillan Publishers Limited.
ISSN0268-3369
2011 Impact Factor: 3.746
2011 SCImago Journal Rankings: 0.315
DOIhttp://dx.doi.org/10.1038/bmt.2011.1
ISI Accession Number IDWOS:000298326500009
Funding AgencyGrant Number
Pfizer Pharmaceuticals
Funding Information:

This study and the drug used in this study were sponsored by Pfizer Pharmaceuticals.

ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLam, DCL
dc.contributor.authorLam, B
dc.contributor.authorWong, MKY
dc.contributor.authorLu, C
dc.contributor.authorAu, WY
dc.contributor.authorTse, EWC
dc.contributor.authorLeung, AYH
dc.contributor.authorKwong, YL
dc.contributor.authorLiang, RHS
dc.contributor.authorLam, WK
dc.contributor.authorIp, MSM
dc.contributor.authorLie, AKW
dc.date.accessioned2011-09-23T05:50:01Z
dc.date.available2011-09-23T05:50:01Z
dc.date.issued2011
dc.description.abstractBronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. © 2011 Macmillan Publishers Limited.
dc.description.naturepostprint
dc.identifier.citationBone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556 [How to Cite?]
DOI: http://dx.doi.org/10.1038/bmt.2011.1
dc.identifier.citeulike8819673
dc.identifier.doihttp://dx.doi.org/10.1038/bmt.2011.1
dc.identifier.epage1556
dc.identifier.hkuros193943
dc.identifier.hkuros193942
dc.identifier.isiWOS:000298326500009
Funding AgencyGrant Number
Pfizer Pharmaceuticals
Funding Information:

This study and the drug used in this study were sponsored by Pfizer Pharmaceuticals.

dc.identifier.issn0268-3369
2011 Impact Factor: 3.746
2011 SCImago Journal Rankings: 0.315
dc.identifier.issue12
dc.identifier.pmid21317934
dc.identifier.scopuseid_2-s2.0-84856096516
dc.identifier.spage1551
dc.identifier.urihttp://hdl.handle.net/10722/139447
dc.identifier.volume46
dc.languageeng
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
dc.publisher.placeUnited Kingdom
dc.relation.ispartofBone Marrow Transplantation
dc.relation.referencesReferences in Scopus
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subjectAzithromycin
dc.subjectBronchiolitis obliterans syndrome (BOS)
dc.subjectHematopoietic SCT (HSCT)
dc.titleEffects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong